Idexx Laboratories (IDXX)
NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$555.67-2.56%
Close 2026-07-08 · 1-day change
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→Idexx grows revenue about 10% a year, led by 14% growth in CAG Diagnostics recurring revenue. Profit margins stay strong near 32%. The company raised its 2026 revenue guidance to about $4.7 billion and EPS outlook to $14.45. Free cash flow remains positive and supports ongoing investments.
Recurring revenue growth could slow if vet visits plateau. Rising costs may pressure profit margins below 31%. Leadership changes and recent soft guidance raise execution risks. If revenue growth falls below 7%, the business model may be weaker than expected.
The stock price is about 28% above our valuation level. Analysts expect roughly 10% revenue growth. Our view is that current estimates are reasonable but leave limited upside given execution risks and valuation.
Breaks if: YoY growth falls below 7% in FY26
IDEXX focuses on expanding CAG Diagnostics recurring revenue, driven by strong volume growth and innovation.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q1. CAG Diagnostics recurring revenue grew 14% as reported and 11% organic. This reflects strong volume growth and innovation, indicating a positive trajectory in line with management's focus.
“CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic.”
Breaks if: EPS falls below $13.00 in FY26
IDEXX raises its 2026 EPS outlook, supported by expectations for increased revenue and operating margin expansion.
Stated in 2 of last 2 quarters. EPS outlook raised to $14.45 - $14.90, reflecting a $0.13 increase at midpoint. Despite the increase, the status remains behind expectations due to limited progress in financial performance.
“Raises 2026 EPS outlook to $14.45 - $14.90, reflecting an increase of $0.13...”
“Projects 2026 EPS of $14.29 - $14.80”
Breaks if: operating margin falls below 30% in FY26
Breaks if: revenue growth falls below 7% in FY26
IDEXX aims to increase its 2026 revenue guidance, reflecting stronger CAG Diagnostics recurring revenue performance.
Stated in 2 of last 2 quarters. Revenue guidance increased to $4,675 million - $4,760 million, reflecting a $42 million increase at midpoint. The trajectory shows persistent focus with limited substantive delivery this quarter.
“Increases 2026 revenue guidance to $4,675 million - $4,760 million, up $42 million...”
“Provides initial outlook for 2026 revenue guidance range of $4,632 million - $4,720 million”